Phase 1 open-label, multi-center clinical study of SMET12 in patients with EGFR-positive advanced solid tumors
Latest Information Update: 14 Jun 2022
At a glance
- Drugs SMET 12 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 14 Jun 2022 New trial record